Stock in Focus: OPKO Health, Inc. (OPK)

Company Profile:

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. In diagnostics, its BioReference Laboratories is the nation’s third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point of care diagnostics platform with PSA and testosterone as the most advanced in development. The Company’s most advanced product utilizing its CTP technology, a once weekly human growth hormone for injection, is in Phase 3 trials, and is partnered with Pfizer. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Recent News:

For the third quarter, the company reported net loss decreased by 23% to $27.7 million or $0.05 a share compared to net loss of $35.9 million or $0.06 per share for the third quarter of 2017. Total revenues improved to $249.8 million, compared to $246.0 million for the third quarter of 2017. The company beat earnings estimates by 2 cents but fell short on revenue expectations by $14.24 million.

The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $3.53 is below its 200-day moving average of $4.48.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



OPK’s strengths can be seen in its strong growth, robust solvency and better efficiency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator, the RSI stands at 54.21 with positive bias. We rate OPKO Health, Inc. (OPK) a STRONG BUY.

About the Author

has written 11914 stories on this site.

Copyright © 2012 Nine Stocks